Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Guideline
. 2003 Aug;89 Suppl 1(Suppl 1):S17-31.
doi: 10.1038/sj.bjc.6601081.

Summary version of the Standards, Options and Recommendations for nonmetastatic breast cancer (updated January 2001)

L Mauriac  1 , E Luporsi, B Cutuli, A Fourquet, J R Garbay, S Giard, F Spyratos, B Sigal-Zafrani, J M Dilhuydy, V Acharian, C Balu-Maestro, M P Blanc-Vincent, C Cohen-Solal, B De Lafontan, M H Dilhuydy, B Duquesne, R Gilles, A Lesur, N Shen, L Cany, I Dagousset, M H Gaspard, H Hoarau, A Hubert, M H Monira, N Perrié, G Romieu; FNCLCC
Affiliations
Guideline

Summary version of the Standards, Options and Recommendations for nonmetastatic breast cancer (updated January 2001)

L Mauriac et al. Br J Cancer. 2003 Aug.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Diagnosis–clinically detectable breast abnormality.
Figure 2
Figure 2
diagnosis–impalpable mammographic abnormality.
Figure 3
Figure 3
Impalpable operable tumour–locoregional treatment.
Figure 4
Figure 4
Operable impalpable tumour–locoregional treatment.
Figure 5
Figure 5
Operable impalpable tumour–locoregional treatment.
Figure 6
Figure 6
Operable palpable tumour–locoregional treatment.
Figure 7
Figure 7
Operable palpable tumour–locoregional treatment.
Figure 8
Figure 8
Operable palpable tumour–locoregional treatment.
Figure 9
Figure 9
Operable palpable tumour–locoregional treatment.
Figure 10
Figure 10
Operable tumour–indication for nodal radiotherapy.
Figure 11
Figure 11
Palpable tumour, breast-conserving surgery not possible.
Figure 12
Figure 12
Palpable tumour, breast-conserving surgery not possible–local treatment after neoadjuvant radiotherapy.
Figure 13
Figure 13
Palpable tumour, breast-conserving surgery not possible: modified radical mastectomy.
Figure 14
Figure 14
Operable tumour–adjuvant treatment.
Figure 15
Figure 15
Operable tumour–adjuvant medical treatment (N+ve, premenopausal woman or ⩽50 years old).
Figure 16
Figure 16
Operable tumour–adjuvant treatment (N+ve, postmenopausal woman or >50 years old).
Figure 17
Figure 17
Operable tumour–adjuvant medical treatment (N−ve, premenopausal woman or ⩽50 years old).
Figure 18
Figure 18
Operable tumour–adjuvant medical treatment (N−ve, postmenopausal woman or >50 years old).
Figure 19
Figure 19
Palpable tumour, breast-conserving surgery not possible–local treatment after neoadjuvant treatment.
Figure 20
Figure 20
Palpable tumour, breast-conserving surgery not possible–local treatment after neoadjuvant radiotherapy.
Figure 21
Figure 21
Standard follow-up.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Fervers B, Hardy J, Blanc-Vincent MP, Theobald S, Bataillard A, Farsi F, Gory G, Debuiche S, Guillo S, Renaud-Salis JL, Pinkerton R, Bey P, Philip T (2001) SOR: project methodology. Br J Cancer 84 (Suppl 2): 8–16 - PMC - PubMed
    1. Mauriac L, Asselain B, Blanc-Vincent MP, Cutuli B, Dilhuydy JM, Fourquet A, Garbay JR, Luporsi E, Spyratos F, Zafrani B (1996) Fédération Nationale des Centres de Lutte Center le Cancer, ed. Cancers du sein non métastatiques, Vol. 3. Paris: Arnette Blackwell; Standards Options et Recommandations
    1. Mauriac L, Luporsi E, Cutuli B, Fourquet A, Garbay JR, Giard S, Spyratos F, Sigal-Zafrani B, Dilhuydy JM, Acharian V, Balu-Maestro C, Blanc-Vincent MP, Cohen-Solal C, De Lafontan B, Dilhuydy MH, Duquesne B, Gilles R, Lesur A, Shen N (2001) Fédération Nationale des Centres de Lutte Contre le Cancer, ed. Cancers du sein infiltrants non métastatiques, Vol 12. Paris: John Libbey EUROTEXT; Standards Options & Recommandations
    1. Mauriac L, Luporsi E, Cutuli B, Fourquet A, Garbay JR, Giard S, Spyratos F, Sigal-Zafrani B, Dilhuydy JM, Acharian V, Balu-Maestro C, Blanc-Vincent MP, Cohen-Solal C, De Lafontan B, Dilhuydy MH, Duquesne B, Gilles R, Lesur A, Shen N (2002) Standards, options and recommendations for non metastatic breast cancer patients. Bull Cancer 89: 207–224 - PubMed
    1. Recommandation du comité d’experts de la Société Française de Radiothérapie Oncologique (SFRO) (1991) Quels volumes cibles ganglionnaires irradiés dans le traitement conservateur du cancer du sein T1-T2≤3 cm N0-n1 (UICC 1987). Bull Cancer Radiother 78: 115–117

Substances